Comparison Between Gastric and Post Pyloric Tube Feedings in Children With Bronchiolitis Requiring High Flow Nasal Cannula
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- The University of Texas Health Science Center at Houston
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- All admitted patients for bronchiolitis requiring high flow nasal cannula therapy at Children's Memorial Hermann
Exclusion Criteria:
- Patients with craniofacial abnormalities that prevent tube placement.
- Patients requiring CPAP and mechanical ventilation are also excluded from the study.
- Patients with past surgeries compromising esophageal sphincter tone such as fundoplication or congenital diaphragmatic hernia surgery are excluded.
- Patients transferred to and from PICU are also excluded from the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: OTHER
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
ACTIVE_COMPARATOR: nasogastric tube (NGT) feeding
|
A nasogastric tube goes from the nose to the stomach.
|
|
ACTIVE_COMPARATOR: nasoduodenal tube (NDT) feeding
|
A nasoduodenal tube goes from the nose to the duodenum.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Length of Respiratory Supprt
Time Frame: from the time of hospital admission to discharge (about 6 days)
|
from the time of hospital admission to discharge (about 6 days)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of Participants With Emesis
Time Frame: from the time of hospital admission to discharge (about 6 days)
|
from the time of hospital admission to discharge (about 6 days)
|
|
Peak Respiratory Support in Liters Per Minute
Time Frame: from the time of hospital admission to discharge (about 6 days)
|
from the time of hospital admission to discharge (about 6 days)
|
|
Number of Chest X-rays Obtained Among All Participants
Time Frame: from the time of hospital admission to discharge (about 6 days)
|
from the time of hospital admission to discharge (about 6 days)
|
|
Number of Participants Who Revisited the Emergency Room (ER)
Time Frame: 7 days after discharge from hospital
|
7 days after discharge from hospital
|
|
Number of Participants Who Revisited the Emergency Room (ER)
Time Frame: 30 days after discharge from hospital
|
30 days after discharge from hospital
|
|
Number of Participants Who Were Readmitted to the Hospital
Time Frame: 7 days after discharge from initial hospital visit
|
7 days after discharge from initial hospital visit
|
|
Number of Participants Who Were Readmitted to the Hospital
Time Frame: 30 days after discharge from initial hospital visit
|
30 days after discharge from initial hospital visit
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- HSC-MS-17-0725
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.